A detailed history of Modus Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Modus Advisors, LLC holds 10,487 shares of GILD stock, worth $942,152. This represents 0.3% of its overall portfolio holdings.

Number of Shares
10,487
Previous 9,810 6.9%
Holding current value
$942,152
Previous $673,000 30.61%
% of portfolio
0.3%
Previous 0.24%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

BUY
$66.59 - $83.99 $45,081 - $56,861
677 Added 6.9%
10,487 $879,000
Q2 2024

Jul 02, 2024

BUY
$63.15 - $72.88 $60,624 - $69,964
960 Added 10.85%
9,810 $673,000
Q1 2024

Apr 02, 2024

BUY
$71.58 - $87.29 $69,146 - $84,322
966 Added 12.25%
8,850 $648,000
Q4 2023

Jan 04, 2024

BUY
$73.27 - $83.09 $120,895 - $137,098
1,650 Added 26.47%
7,884 $638,000
Q3 2023

Oct 20, 2023

BUY
$73.94 - $80.67 $43,476 - $47,433
588 Added 10.41%
6,234 $467,000
Q2 2023

Jul 05, 2023

BUY
$76.01 - $86.7 $37,320 - $42,569
491 Added 9.52%
5,646 $435,000
Q1 2023

Apr 04, 2023

BUY
$77.31 - $88.08 $4,715 - $5,372
61 Added 1.2%
5,155 $427,000
Q4 2022

Jan 05, 2023

BUY
$62.32 - $89.47 $65,934 - $94,659
1,058 Added 26.21%
5,094 $0
Q3 2022

Oct 05, 2022

BUY
$59.54 - $68.01 $1,667 - $1,904
28 Added 0.7%
4,036 $249,000
Q2 2022

Jul 05, 2022

BUY
$57.72 - $65.01 $10,793 - $12,156
187 Added 4.89%
4,008 $248,000
Q1 2022

Apr 05, 2022

BUY
$57.92 - $72.58 $45,872 - $57,483
792 Added 26.15%
3,821 $227,000
Q4 2021

Jan 04, 2022

BUY
$64.88 - $73.64 $196,521 - $223,055
3,029 New
3,029 $220,000
Q3 2021

Oct 08, 2021

SELL
$67.69 - $73.03 $110,199 - $118,892
-1,628 Closed
0 $0
Q2 2021

Jul 01, 2021

BUY
$63.47 - $69.35 $103,329 - $112,901
1,628 New
1,628 $112,000
Q3 2020

Oct 01, 2020

SELL
$62.1 - $78.08 $30,987 - $38,961
-499 Closed
0 $0
Q2 2020

Jul 01, 2020

BUY
$72.34 - $84.0 $36,097 - $41,916
499 New
499 $38,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Modus Advisors, LLC Portfolio

Follow Modus Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Modus Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Modus Advisors, LLC with notifications on news.